Connect with us

Technology

Dräger expands neonatal care portfolio with BiliPredics software solution

Published

on

Innovative digital application predicts bilirubin, the biomarker for neonatal jaundice, helping to enhance early intervention and care

TELFORD, Penn., March 24, 2025 /PRNewswire/ — Dräger is expanding its neonatal care portfolio with the introduction of BiliPredics, a predictive software solution from NeoPredics designed to forecast dynamic progression of bilirubin. By leveraging a clinically validated algorithm, BiliPredics can enable healthcare professionals to anticipate bilirubin progression up to 60 hours in advance, helping to support timely and informed clinical decisions.

“Our collaboration with Dräger is a significant milestone in advancing neonatal care.”

Key Benefits of BiliPredics:

Enhanced Discharge Planning: Supports clinicians to help reduce unnecessary treatments, tests, and extended hospital stays through predictive insights into bilirubin progression.

Data-Driven Decision Making: Utilizes an extensive database of over 50,000 individual bilirubin measurements of close to 10,000 newborns with a total of about 100,000 individual patient characteristics. Integrated Jaundice Management: Helps provide a streamlined pathway for screening, monitoring, and treating neonatal jaundice.

Advanced predictive capabilities

Neonatal jaundice affects approximately 50% of all newborns and up to 80% of premature babies.1 BiliPredics offers a proactive approach to jaundice management by forecasting bilirubin progression over 30, 48, or 60 hours. The web-based application presents this data in an accessible dashboard, helping to enable clinicians to implement preventive measures and reduce the risk of complications.

Smooth integration with clinical workflows

BiliPredics requires only a few clinical parameters to generate comprehensive insights. It aligns with established guidelines, including the 2022 AAP Hyperbilirubinemia Guideline, and can integrate with electronic medical records (EMR) to display patient data within the dashboard. The system presents bilirubin trends through comprehensible curves, helping to allow for real-time assessment and intervention.

Strategic partnership to advance neonatal care

“Through our partnership with NeoPredics, we are expanding our offering with an innovative digital solution that strengthens our position as a leader in jaundice management,” said Harald Kneuer, director of neonatal care at Dräger. “By combining Dräger’s market expertise with NeoPredics’ advanced predictive analytics, we are providing healthcare professionals with powerful tools to improve patient outcomes while managing costs.”

NeoPredics CEO, Thorsten Waloschek, echoed this sentiment: “Our collaboration with Dräger is a significant milestone in advancing neonatal care. Together, we are bridging innovative technology and clinical expertise to address critical challenges in jaundice management worldwide.”

Comprehensive jaundice management solutions

Dräger’s neonatal care portfolio includes solutions for both screening and treatment of neonatal jaundice. The Dräger Jaundice Meter JM-105 offers non-invasive, rapid bilirubin measurement, while the BiliLuxTM Phototherapy Light provides effective LED-based phototherapy for jaundice treatment. This approach helps ensure adherence to the latest guidelines, reinforcing the concept of “phototherapy as a drug” with precise irradiance dosing.

About Dräger

Dräger is a leading international medical and safety technology company. Our products protect, support and save lives. Founded in 1889, Dräger generated global sales of around EUR 3.4 billion in 2023. The Lübeck-based company is represented in more than 190 countries and employs more than 16,000 people worldwide. For more information, visit www.draeger.com

NeoPredics
NeoPredics is a leader in predictive analytics and clinical decision support, with a focus on maternal and neonatal health. Committed to improving outcomes for women and children, NeoPredics develops state-of-the-art solutions like the FDA-registered and CE-certified Bilipredics jaundice management solution, addressing critical challenges in care with innovation and precision. For more information, visit www.neopredics.com

Note: The solution mentioned in this press release will not initially be available in all countries. For more information on the availability of products in your country, please visit the respective country website or contact the local Dräger sales organization.

1Jardine LA, Woodgate P: Neonatal jaundice: phototherapy, ClinicalEvidence 2015;05:319, BMJ Publishing Group

Contact
Communications: Melanie Kamann, Tel. +49 451 882-3202, melanie.kamann@draeger.com
Press Contact North America: Laura Edwards, Tel. +1 215 565-5868, laura.edwards@draeger.com
Investor Relations: Thomas Fischler, Tel. +49 451 882-2685, thomas.fischler@draeger.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/drager-expands-neonatal-care-portfolio-with-bilipredics-software-solution-302406171.html

SOURCE Draeger

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

IRBM Expands Functional Genomics Platform to Strengthen Early Drug Discovery

Published

on

By

De-Risking Target Validation with Data-Driven Genomic Insights

ROME, April 3, 2025 /PRNewswire/ — IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug discovery, has established a comprehensive Functional Genomics Platform to support genetic target identification and validation, and generation of disease-relevant cellular models. The platform integrates CRISPR-based methodologies, screening capabilities, cell engineering, and advanced molecular and cellular analysis to drive both target discovery and validation.

To further enhance target validation, IRBM is expanding its genome editing toolkit with CRISPR tiling to systematically map functional domains within coding and regulatory regions, along with base and prime editing to introduce precise nucleotide modifications. These next-generation approaches—combined with the platform’s high-throughput CRISPR screening, including stem cell engineering—are instrumental in building robust disease models and improving the reliability of target validation.

“Understanding which targets are truly viable for drug development is a complex challenge,” said Sara Tomaselli, PhD, Head of Functional Genomics at IRBM. “With this in-house platform, we’re strengthening our ability to systematically evaluate gene function, de-risk early discovery, and support our partners in making well-informed decisions.”

The platform’s screening capabilities include genome-wide and targeted CRISPR libraries for knockout (CRISPR KO), inhibition (CRISPRi), and activation (CRISPRa), enabling in-depth exploration of gene function and associated pathways. In parallel, IRBM’s cell engineering expertise—spanning patient-relevant models and iPSC-derived systems—supports disease modeling across oncology, neurodegeneration, and rare disorders. Multi-omics integration, including high-content imaging, single-cell transcriptomics, and proteomics, provides deeper functional characterization of drug targets.

IRBM’s Functional Genomics Platform is part of a broader, fully integrated drug discovery ecosystem, ensuring that genetic insights translate into meaningful preclinical models and drug development strategies. By combining functional genomics with expertise in medicinal chemistry, biomarker discovery, and preclinical pharmacology, IRBM enables biopharma innovators to approach target validation with greater confidence.

“We take a careful, methodical approach to functional genomics—one that integrates well with the complexities of drug discovery,” said Carlo Toniatti, MD, PhD, Chief Scientific Officer at IRBM. “Our goal is to help our partners uncover high-quality targets and generate data that can guide and inform decision making throughout the entire drug discovery process.”

IRBM’s collaborative approach allows biotech startups, pharmaceutical companies, and venture-backed teams to access functional genomics expertise without the need for in-house infrastructure. With customized solutions spanning genetic screening, engineered cell models, and mechanistic studies, IRBM provides practical, scientifically rigorous support at key points in drug discovery.

To learn more about IRBM’s Functional Genomics Platform and collaboration opportunities, visit www.irbm.com.

About IRBM

IRBM is a contract research organization (CRO) focused on early-stage drug discovery. With a track record of delivering preclinical candidates across oncology, neurodegeneration, and infectious diseases, IRBM partners with biotech and pharmaceutical innovators to advance therapeutic development with scientific precision and transparency.

 

SOURCE IRBM S.p.A.

Continue Reading

Technology

NECA Applauds President Trump’s Leadership on Tariffs and the Impact on the Electrical Industry

Published

on

By

WASHINGTON, April 2, 2025 /PRNewswire/ — The National Electrical Contractors Association (NECA) applauds President Donald J. Trump’s strong leadership in addressing critical national priorities, including strengthening American manufacturing, securing our borders, and revitalizing our economy. As an association representing thousands of electrical contractors nationwide, we share his vision for a more resilient domestic supply chain and a thriving workforce.

The National Electrical Contractors Assoc. applauds Pres. Trump’s leadership in strengthening American manufacturing.

At the same time, NECA remains mindful of the potential impacts that the newly announced tariffs may have on the electrical construction industry. With a global supply chain integral to our work, increased costs on key materials such as copper wiring, transformers, work vehicles and electrical products could pose challenges for contractors, project timelines, and infrastructure development.

That said, we appreciate the Administration’s efforts to support American businesses and are encouraged that several key materials critical to the electrical construction industry—such as copper, semiconductors, steel, and aluminum—are not subject to these new reciprocal tariffs. Ensuring access to these essential goods at competitive prices is vital to the success of our contractors and the broader economy.

“President Trump has consistently prioritized policies that put the electrical industry as a priority, and we recognize his commitment to strengthening our nation’s economy,” said David Long, NECA’s Chief Executive Officer.

NECA encourages its members to proactively prepare for potential shifts in pricing and availability by:

Strengthening Supplier Partnerships – Exploring new domestic sourcing opportunities while reinforcing existing relationships to maintain project efficiency.Adapting Contract Strategies – Reviewing and adjusting contracts to accommodate material cost fluctuations and ensure long-term project sustainability.Engaging in Policy Dialogue – Collaborating with industry leaders and policymakers to support a balanced approach that protects American businesses and workers.

The electrical construction industry plays a vital role in America’s infrastructure and economic growth. NECA is committed to working alongside the administration and industry stakeholders to uphold the strength, innovation, and competitiveness of U.S. electrical contractors.

Long concluded, “As these new tariffs take effect, we look forward to working with the Administration to ensure that electrical contractors and the entire electrical industry can continue powering America efficiently while navigating potential cost and supply chain challenges.”

ABOUT THE NATIONAL ELECTRICAL CONTRACTORS ASSOCIATION
NECA is the voice of the $255 billion electrical construction industry that brings power, light, and communication technology to buildings and communities across North America. NECA’s national office and 118 local chapters advance the industry through advocacy, education, research, and standards development. Go to www.necanet.org for more information.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neca-applauds-president-trumps-leadership-on-tariffs-and-the-impact-on-the-electrical-industry-302419124.html

SOURCE National Electrical Contractors Assoc Inc.

Continue Reading

Technology

Blackpearl Group announces US-based COO to drive aggressive growth strategy

Published

on

By

PHOENIX, April 2, 2025 /PRNewswire/ — Blackpearl Group Limited (NZX:BPG) has appointed Christie Kerner as its Chief Operating Officer (COO) to support the company’s strategic go-to-market (GTM) strategy and drive its next phase of growth in the US market. With over 30 years of experience scaling companies of all sizes, leading global teams and driving operational excellence, Kerner will play a pivotal role in strengthening Blackpearl Group’s leadership team as it accelerates expansion.

“The US is our primary market and local expertise is key to our success. To do this, we need to secure world-class talent with the chops, experience and proven ability to align company operations with trajectory,” comments Nick Lissette, Founder and Chief Executive Officer of Blackpearl Group.

With extensive experience in both high-growth startups and profitable, long-term businesses, Kerner brings a rare ability to balance ambition with structure. “Her leadership will be instrumental in ensuring Blackpearl Group scales effectively while preserving the ingenuity and agility that set us apart,” adds Lissette.

Leading from the US – scaling with vision

Kerner will be based in the US and will work to closely align the company’s US and NZ teams. Her focus will be on building the infrastructure needed to support long-term success. “We’re sitting on a launchpad right now – our trajectory is set and my role is to refine our strategies, remove barriers and shape the rocketship for sustainable growth,” she says.

“Scaling isn’t just about growth though – it’s about ensuring the right people are in the right seats, that priorities are aligned and that we’re disciplined in execution,” explains Kerner. “I focus on creating an environment where people thrive – because when they do, the businesses will thrive.”

A track record of leadership and impact

With a Master’s in Management and Leadership, Kerner’s career spans senior leadership roles across startups, corporates and academia where she is renowned for her ability to balance aggressive growth with sound fiscal strategy, ensuring businesses scale effectively while maintaining strong foundations.

Kerner has been instrumental in shaping the growth-stage startup ecosystem in the US, helping companies as they scale toward $200M+ in revenue. As a board member of StartupAZ and Founder of the Founders Collective, she has championed high-growth founders navigating this critical phase and has scaled international programs with Startup Grind.

Kerner has also built and exited multiple companies and served as an Entrepreneur in Residence advising founders on growth, leadership and decision-making. Previously, she led the Center for Entrepreneurship at Arizona State University’s W. P. Carey School of Business (the largest public university in the US) and was Executive Director of Student Entrepreneurship across ASU.

“This experience aligns seamlessly with Blackpearl Group’s trajectory as it moves beyond $11M in ARR and into its next stage of growth,” adds Lissette.

A billion-dollar vision

“AI and emerging technologies can disrupt markets overnight,” notes Kerner, adding that “Success lies in building resilience and that’s rooted in an ability to innovate on an ongoing basis.”

Blackpearl Group leverages a portfolio approach to product development within a rapidly evolving tech landscape, reflected in the development of Bebop, the company’s AI-powered sales intelligence tool, in a single quarter. Bebop is a game-changer for SMEs, offering powerful sales intelligence at a fraction of the cost of competitors like ZoomInfo, Kaspr and Apollo. The beta launch of Bebop follows the success of Pearl Diver, Blackpearl Group’s flagship prospect identification platform. Pearl Diver is a marketing intelligence platform which offers businesses a way of off-setting their reliance on traditional pay-to-play ad platforms.

“Under Nick’s progressive leadership, we have the potential to be a billion-dollar company. Importantly, we’re not building that success around a single product – we’re creating a portfolio of solutions that balance high-risk innovation with consistent, long-term performance,” she adds.

“Christie shares a belief that’s been fundamental to our success so far: it’s time to stop playing small. This appointment brings together ambition, strategy and the discipline to execute at scale and I’m excited to see its effects,” concludes Lissette.

About Blackpearl Group (NZX: BPG)

Blackpearl Group is a market-leading data technology company that pioneers AI-driven, sales and marketing solutions for the US market. 

Specifically engineered for small-medium-sized businesses (SMEs), Blackpearl Group consistently delivers exceptional value to its customers. Our mantra is simple: ‘Creating Motivating Opportunities.’ 

Blackpearl creates the opportunities that motivate action. We create high-impact products that pivot at speed to serve what businesses really need, kick-starting action – turning data into dollars. 

Founded in 2012, Blackpearl Group is based in Wellington, New Zealand, and Phoenix, Arizona. blackpearl.com 

 

View original content:https://www.prnewswire.com/news-releases/blackpearl-group-announces-us-based-coo-to-drive-aggressive-growth-strategy-302419103.html

SOURCE Blackpearl Group Limited

Continue Reading

Trending